Sino Biopharm reports 10.60 percent growth for Sino Biopharm stock

Published on 10/15/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 10.60 percent to RMB 19.44 billion in first-half 2026. Sino Biopharm stock costs EUR 0.60 on October 15, 2026, up 1.93 percent versus HKEX close.

Revenue growth and market valuation

Sino Biopharm reported first-half revenue of RMB 19.44 billion on September 24, 2026, up 10.60 percent.
Underlying profit increased 8.10 percent to RMB 3.34 billion in the first half of 2026.
Sino Biopharm stock costs EUR 0.60 at Lang & Schwarz on October 15, 2026 at 9:35 p.m. CEST, up 1.93 percent versus the HKEX close of October 14, 2026.
The stock has a P/E ratio of 33.99 and a market capitalization of HKD 93.9 billion as of October 15, 2026.

Sino Biopharm, KYG8167W1380, Illustration mit AI erstellt.

Sino Biopharm reported first-half revenue of RMB 19.44 billion, up 10.60 percent from the same period of 2025, giving the pharmaceutical group a measurable growth anchor for its stock. FinancialFilings dated the interim report September 24, 2026. Sino Biopharm stock was at EUR 0.60 at Lang & Schwarz on October 15, 2026 at 9:35 p.m. CEST, while the Hong Kong listing was up 1.93 percent against its October 14, 2026 close.

Growth extends beyond revenue

The earnings mix gives investors a second metric. Underlying profit rose 8.10 percent year over year to RMB 3.34 billion in the first half of 2026, while reported profit attributable to owners increased 1.40 percent to RMB 3.43 billion, according to Futubull.

Innovation drugs and out-licensing generated RMB 8.79 billion in the first half, up 44.30 percent year over year and equal to 45.20 percent of revenue. That comparison is important because it shows the faster-growing business line expanding its contribution beyond the overall 10.60 percent revenue increase.

Price position after Hong Kong trading

Sino Biopharm was last at HKD 5.27 on the Hong Kong Stock Exchange on October 15, 2026 at 4:08 p.m. HKT, versus HKD 5.17 previously. The company trades under stock code 1177 and the ISIN is KYG8167W1380, as documented by Global Banking and Finance.

Valuation and peer comparison

The market capitalization was HKD 93.9 billion and the P/E ratio was 33.99 as of October 15, 2026. The trailing dividend yield was 0.02 percent, keeping the valuation discussion focused on earnings growth rather than income.

Comparison with peers

Sino Biopharm (HKEX, HKD): plus 1.93 percent, P/E 33.99, market capitalization HKD 93.9 billion
Sinopharm Group (HKEX, HKD): plus 0.32 percent, P/E 5.93, market capitalization HKD 48.8 billion
Shanghai Fosun Pharmaceutical (HKEX, HKD): minus 0.41 percent, P/E 18.12, market capitalization HKD 64.2 billion

Market value and trading phase

The EUR 0.60 quote reflects the after-hours phase in Berlin, while the Hong Kong session had already ended. For investors, the key contrast is the company's 10.60 percent first-half revenue growth against a valuation that remains tied to future earnings expansion.

Sino Biopharm was trading at EUR 0.60 at Lang & Schwarz on October 15, 2026 at 9:35 p.m. CEST. The Hong Kong listing stood at HKD 5.27 at 4:08 p.m. HKT on the same date, up 1.93 percent versus the HKD 5.17 close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Sino Biopharm stock.